Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Copanlisib

Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity[1].

Product Specifications

CAS Number

1032568-63-0

Product Name Alternative

BAY 80-6946

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; PI3K

Type

Reference compound

Related Pathways

Apoptosis; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BAY-80-6946.html

Purity

99.35

Smiles

O=C(C1=CN=C(N)N=C1)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C5=NCCN25

Molecular Formula

C23H28N8O4

Molecular Weight

480.52

Precautions

H302, H315, H319, H335

References & Citations

[1]Liu N, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013 Nov;12 (11) :2319-30.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ

Citation 01

Bioorg Chem. 2025 Apr 5:160:108424.|Blood Adv. 2022 Apr 12;6 (7) :2346-2360.|Blood. 2019 Jan 3;133 (1) :70-80.|Br J Cancer. 2025 Oct 6.|Breast Cancer Res Treat. 2020 Jan;179 (2) :337-347.|Cancer Discov. 2025 Jan 13;15 (1) :202-226.|Cancer Lett. 2022 Jan 1:524:151-160.|Carbohydr Polym. 2024 Feb 15:326:121637.|Cell Biosci. 2020 Feb 12;10:16.|Cell Biosci. 2022 Aug 2;12 (1) :122.|Cell Biosci. 2022 Dec 30;12 (1) :210.|Front Immunol. 2021 Oct 15;12:699478.|Front Oncol. 2021 Jul 13:11:704042.|Genes Dis. 2021 Jul 1;9 (6) :1650-1661.|J Clin Invest. 2021 Dec 15;131 (24) :e140436.|J Immunother Cancer. 2022 Mar;10 (3) :e003402.|J Oncol. 2022 Apr 29;2022:1515416.|Mol Cancer Ther. 2025 Jul 10.|Mol Cancer. 2023 Mar 30;22 (1) :64.|Mol Cancer. 2024 Sep 30;23 (1) :215.|Mol Carcinog. 2024 Apr 17|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Nat Cancer. 2024 Aug;5 (8) :1250-1266.|RSC Adv. 2019 Feb 21;9 (11) :6409-6418.|Sci Rep. 2025 Aug 10;15 (1) :29265.|Science. 2017 Dec 1;358 (6367) :eaan4368.|Signal Transduct Target Ther. 2025 Oct 31;10 (1) :356.|Theranostics. 2020 Jan 1;10 (4) :1531-1543.|Université de Lausanne. 2024 Feb 7.|bioRxiv. 2025 Jan 16:2025.01.10.632413.|Br J Cancer. 2025 Oct 6.|Front Oncol. 2022 Sep 8:12:944537.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

TDP-25/TDP-35/TDP-43 Antibody (HRP)
KH-2914-01 50 μL

TDP-25/TDP-35/TDP-43 Antibody (HRP)

Sign In for Pricing
View Details
TDP-25/TDP-35/TDP-43 Antibody (HRP)
KH-2914-02 100 µL

TDP-25/TDP-35/TDP-43 Antibody (HRP)

Sign In for Pricing
View Details
TDP-25/TDP-35/TDP-43 Antibody (HRP)
KH-2914-03 1 mL

TDP-25/TDP-35/TDP-43 Antibody (HRP)

Sign In for Pricing
View Details
Tissue Genomic DNA, Lung
CD564913 5 µg

Tissue Genomic DNA, Lung

Sign In for Pricing
View Details
EDF1 Rabbit Polyclonal Antibody
TA375711 100 µL

EDF1 Rabbit Polyclonal Antibody

Sign In for Pricing
View Details
IFI35 Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI2B9]
TA503357AM 100 µL

IFI35 Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI2B9]

Sign In for Pricing
View Details